UniProtKB/Swiss-Prot Q14973 : Variant p.Arg252His
Hepatic sodium/bile acid cotransporter
Gene: SLC10A1
Feedback ?
Variant information
Variant position:
252
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Arginine (R) to Histidine (H) at position 252 (R252H, p.Arg252His).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and basic (R) to medium size and polar (H)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In FHCA2; loss of function in taurocholate transport; loss of localization to the cell membrane due to intracellular retention.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
252
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
349
The length of the canonical sequence.
Location on the sequence:
IGFLLGYVLSALFCLNGRCR
R TVSMETGCQNVQLCSTILNV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human IGFLLGYVLSALFCLNGRCRR TVSMETGCQNVQLCSTILNV
Mouse TGFLMGYILSALFRLNPSCRR TISMETGFQNVQLCSTILNV
Rat SGFLMGYILSALFQLNPSCRR TISMETGFQNIQLCSTILNV
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 349
Hepatic sodium/bile acid cotransporter
Transmembrane
248 – 273
Discontinuously helical; Name=8
Mutagenesis
261 – 261
Q -> A. Abolishes interaction with HBV myristoylated pre-S1 peptide.
Mutagenesis
263 – 263
V -> W. Disrupts interaction with HBV myristoylated pre-S1 peptide.
Mutagenesis
264 – 264
Q -> AW. Disrupts interaction with HBV myristoylated pre-S1 peptide, reduces bile acid transport and reduces HBV infection.
Mutagenesis
268 – 268
T -> W. Disrupts interaction with HBV myristoylated pre-S1 peptide, reduces bile acid transport and reduces HBV infection.
Mutagenesis
272 – 272
V -> W. Disrupts interaction with HBV myristoylated pre-S1 peptide, reduces bile acid transport and reduces HBV infection.
Helix
248 – 259
Literature citations
Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype.
Vaz F.M.; Paulusma C.C.; Huidekoper H.; de Ru M.; Lim C.; Koster J.; Ho-Mok K.; Bootsma A.H.; Groen A.K.; Schaap F.G.; Oude Elferink R.P.; Waterham H.R.; Wanders R.J.;
Hepatology 61:260-267(2015)
Cited for: FUNCTION; SUBCELLULAR LOCATION; VARIANT FHCA2 HIS-252; CHARACTERIZATION OF VARIANT FHCA2 HIS-252; TRANSPORT ACTIVITY; BIOPHYSICOCHEMICAL PROPERTIES;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.